Novo Nordisk's investigational triple agonist UBT251 (targeting GLP-1, GIP, and glucagon) delivered up to 19.7% mean weight loss in just 24 weeks in a Phase 2 trial conducted in China
These people's metabolism have been completely shut off for their, much of their lives, you know, and obviously you have to weigh risk versus benefit with your clinician, your, you know, your practitioner, and I encourage everyone to do that
Image: Canva Think about including particular items in your diet to increase glutathione levels organically
By reducing appetite and cravings, Wegovy helps to lower calorie intake without engaging the struggle of constant hunger
The trial investigated the effects of stopping semaglutide treatment in people with obesity
Stacking aggressive calorie restriction on top risks severe muscle loss and rebound when you eventually taper